Compare BRLT & SKYE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BRLT | SKYE |
|---|---|---|
| Founded | 2005 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Consumer Specialties | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 22.5M | 24.2M |
| IPO Year | 2021 | 2013 |
| Metric | BRLT | SKYE |
|---|---|---|
| Price | $1.15 | $0.73 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 3 |
| Target Price | $1.70 | ★ $15.00 |
| AVG Volume (30 Days) | 62.0K | ★ 190.3K |
| Earning Date | 05-06-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $437,483,000.00 | N/A |
| Revenue This Year | $6.72 | N/A |
| Revenue Next Year | $4.95 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 3.63 | N/A |
| 52 Week Low | $1.12 | $0.57 |
| 52 Week High | $3.10 | $5.75 |
| Indicator | BRLT | SKYE |
|---|---|---|
| Relative Strength Index (RSI) | 37.10 | 41.17 |
| Support Level | N/A | $0.71 |
| Resistance Level | $1.64 | $0.83 |
| Average True Range (ATR) | 0.10 | 0.08 |
| MACD | -0.03 | -0.02 |
| Stochastic Oscillator | 18.75 | 3.29 |
Brilliant Earth Group Inc is an digitally native omnichannel jewelry company selling The company's products include rings, necklaces, earrings, and bracelets. Its collection of premium-quality diamond engagement and wedding rings, gemstone rings, and fine jewelry is conceptualized by in-house design studio. The company operates in one operating and reporting segment, the retail sale of diamonds, gemstones and jewelry.
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.